Understanding how specific lung cells evolve into cancer due to smoking.
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10897085
This study is looking at how certain lung cells change early on when someone is at risk of developing lung cancer, especially from smoking, to find new ways to help prevent or treat the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10897085 on ClinicalTrials.gov |
What this research studies
This research investigates the early changes in lung cells that lead to lung adenocarcinomas, particularly focusing on the role of Krt8+ alveolar cells in the progression from normal lung tissue to cancerous lesions. By utilizing advanced techniques like single-cell RNA sequencing, the study aims to identify molecular and immune changes associated with tobacco exposure and how these contribute to the development of lung cancer. The goal is to uncover potential targets for early intervention and treatment, which could significantly improve outcomes for patients at risk of lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of smoking who are at risk for developing lung cancer.
Not a fit: Patients who have never smoked or have non-lung-related cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and more effective treatments for lung cancer in smokers.
How similar studies have performed: Previous research has shown promising results in understanding lung cancer development through similar cellular and molecular approaches.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KADARA, HUMAM — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: KADARA, HUMAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Causing Agents, Cancer Genes, Cancer-Promoting Gene, Cancers